Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan

Heart failure is an increasingly common condition that can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition. One such drug, called Sacubitril/valsartan (SV) has been shown to reduce hospitalizations and prolong life expectancy of patients with heart failure. It works by reversing some of the structural and functional changes to the heart that occur in heart failure. However, not all patients respond to the drug. Further research is needed to better understand the reasons for this and predict who will benefit most from the drug. Left atrial strain is a relatively new measurement that can be obtained using ultrasound imaging of the heart, and it provides objective information about how one of the heart's four chambers is functioning. The investigators aim to assess the effect of SV therapy on left atrial strain in patients with heart failure. The investigator's objective is to understand whether abnormal left atrial strain or changes in left atrial strain help predict response to SV therapy.

NCT Number	NCT07088471
Lead Sponsor	Connolly Hospital Blanchardstown
Conditions	Heart Failure and Reduced Ejection Fraction
Enrollment	334 participants
Start Date	2024-11-01
Primary Completion	2025-05-01 (estimated)
Study Completion	2025-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-13